' k% r$ y6 B6 s+ l, e
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:0 d: a/ e6 k3 p# \" g
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer." v( A9 _; k% O& t! P! H http://www.ncbi.nlm.nih.gov/pubmed/22968184; f A0 i h; t B( \! p
7 m3 a; Q1 [- o2 F
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 5 b& Y, H$ H" N2 q* x3 Chttp://d.wanfangdata.com.cn/Thesis_Y1770447.aspx